Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.55 |
| ▸ | CYP2A13 | Q16696 | 5/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | GPR183 | P32249 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10104471 | 0.82 | PDE3B (0.55) | PDE3BPDE3ACYP2A13HSD17B10CYP2C9 | |
| SCHEMBL18580987 | 0.82 | GPR183 (0.48) | PDE3BPDE3ANR1H2GPR183ALDH1A1 | |
| SCHEMBL2435935 | 0.82 | NR1H2 (0.70) | PDE3BPDE3ACYP2A13HSD17B10CYP2C9 | |
| SCHEMBL30900087 | 0.82 | NR1H2 (0.70) | PDE3BPDE3ACYP2A13HSD17B10CYP2C9 | |
| SCHEMBL5254444 | 0.81 | CYP2C9 (0.58) | CYP2A13HSD17B10CYP2C9ALOX15CCR5 | |
| SCHEMBL1930020 | 0.80 | CYP2A13 (0.61) | CYP2A13HSD17B10CYP2C9ALOX15CCR5 | |
| SCHEMBL13612079 | 0.80 | PDE3B (0.53) | PDE3BPDE3ACYP2A13HSD17B10CYP2C9 | |
| SCHEMBL15237068 | 0.80 | PDE3B (0.50) | PDE3BPDE3ACYP2A13HSD17B10CYP2C9 | |
| SCHEMBL15859936 | 0.78 | KDM4E (0.67) | CYP2A13HSD17B10CYP2C9ALOX15ALDH1A1 | |
| SCHEMBL24192812 | 0.78 | NR1H2 (0.47) | NR1H2GPR183ALDH1A1KDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101678020-B | Quinoxaline derivatives as inhibitors of the tyrosine kinase activity of Janus kinases | NOVARTIS AG | 2012-08-15 | — | — | CN | disclosed |
| EP-2155201-B1 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| EP-2155201-B1 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| CN-101678020-A | Quinoxaline derivatives as inhibitors of the tyrosine kinase activity of Janus kinases | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| EP-2155201-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008148867-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008148867-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | JAK2, JAK1, JAK3 | PDE3B 970/4885PDE3A 1113/4885CYP2A13 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.